Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation Academic Article uri icon

Overview

MeSH Major

  • Leukemia, Myeloid, Acute
  • Mutation
  • Stem Cell Transplantation
  • fms-Like Tyrosine Kinase 3

abstract

  • © 2015. Following chemotherapy, patients with acute myelogenous leukemia (AML), normal cytogenetics, and the FLT3-ITD mutation have shorter survival compared to wild type (WT) patients. To determine the role of stem cell transplantation (SCT), we performed a retrospective review of adult patients with AML who underwent SCT at our center between January 1, 2007 and December 31, 2011. Of the 200 patients transplanted, 79 patients (40%) had normal cytogenetics; of these, 17 (22%) had the FLT3-ITD mutation, 35 were WT (44%), and 27 (34%) did not have FLT3 testing performed. Clinical characteristics were similar in each group. At four years, overall survival (OS) between FLT3 positive and WT groups was similar: 0.54 (95% CI 0.29-0.75) versus 0.73 (95% CI 0.53-0.99), p = 0.18. Relapse rates were also similar, 0.09 (95% CI 0.02-0.21) versus 0.12 (95% CI: 0.02-0.32); p = 0.67. We conclude that SCT can abrogate the poor prognosis in FLT3-ITD positive patients.

publication date

  • August 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5053396

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2015.11.010

PubMed ID

  • 26692109

Additional Document Info